Early recognition, evaluation and treatment may prevent blindness in giant cell arteritis

References

• Kearns TP. Collagen and rheumatic diseases: ophthalmic aspects. In: The Eye and Systemic Disease. Mausolf FA (Ed.). Mosby, MO, USA 114–118 (1975).
   Google Scholar
• Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis a decision-analytic approach. Ophthalmology112(5), 744–756 (2005).
   PubMed Web of Science ®Google Scholar
• Jafre HS, Sofianos C, Hattab EM, Overhiser A, Chiorean M. Temporal arteritis presenting with gastrointestinal symptoms in a middle aged man. J. Gen. Intern. Med.21(7), 796 (2006).
   Google Scholar
• Eshaghian J. Controversies regarding giant cell (temporal, cranial) arteritis. Doc. Ophthalmol.47(1), 43–67 (1979).
   PubMed Web of Science ®Google Scholar
• Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann. Intern. Med.88(2), 162–167 (1978).
   PubMed Web of Science ®Google Scholar
• Liu NH, LaBree LD, Feldon SE. The epidemiology of giant cell arteritis: a 12-year retrospective study. Ophthalmology108(6), 1145–1149 (2001).
   PubMed Web of Science ®Google Scholar
• Rahman W, Rahman FZ. Giant cell (temporal) arteritis: an overview and update. Surv. Ophthalmol.50(5), 415–428 (2005).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum.51(2), 264–268 (2004).
   PubMed Web of Science ®Google Scholar
• Tomsak RL. Giant cell arteritis. Ophthalmology109(2), 219–220 (2002).
   PubMedGoogle Scholar
• Grosser SJ, Reddy RK, Tomsak RL, Katzin WE. Temporal arteritis in African Americans. Neuroophthalmology21(1), 25–31 (1999).
   Web of Science ®Google Scholar
• Nordborg C, Johansson H, Petursdottir1 V, Nordborg E. The epidemiology of biopsy-positive giant cell arteritis: special reference to changes in the age of the population. Rheumatology (Oxf.)42(4), 549–552 (2003).
   PubMed Web of Science ®Google Scholar
• Nordborg C, Nordborg E, Petursdottir V. Giant cell arteritis. Epidemiology, etiology and pathogenesis. Apmis108(11), 713–724 (2000).
   PubMed Web of Science ®Google Scholar
• Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin. Proc.51(8), 504–510 (1976).
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann. Intern. Med.139(6), 505–515 (2003).
   PubMed Web of Science ®Google Scholar
• Lichtstein DM, Caceres LR. Heeding clues to giant cell arteritis. Prompt response can prevent vision loss. Postgrad. Med.115(5), 91–95 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Balt.)84(5), 269–276 (2005).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am. J. Ophthalmol.123(3), 285–296 (1997).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am. J. Ophthalmol.125(4), 509–520 (1998).
   PubMed Web of Science ®Google Scholar
• Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br. J. Rheumatol.36(2), 251–254 (1997).
   PubMedGoogle Scholar
• Hayreh SS, PA Podhajsky, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am. J. Ophthalmol.125(4), 521–526 (1998).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica217(4), 239–259 (2003).
   PubMed Web of Science ®Google Scholar
• Jonasson F, Cullen JF, Elton RA. Temporal arteritis. A 14-year epidemiological, clinical and prognostic study. Scott. Med. J.24(2), 111–117 (1979).
   PubMed Web of Science ®Google Scholar
• Biousse V, Touboul P, D’Anglejan-Chatillon J, Le’Vy C, Schaison M, Bousser M. Ophthalmologic manifestations of internal carotid artery dissection. Am. J. Ophthalmol.126, 565–577 (1998).
   PubMed Web of Science ®Google Scholar
• Siatkowski RM, Gass JD, Glaser JS, Smith JL, Schatz NJ, Schiffman J. Fluorescein angiography in the diagnosis of giant cell arteritis. Am. J. Ophthalmol.115(1), 57–63 (1993).
   PubMed Web of Science ®Google Scholar
• Mack HG, O’Day J, Currie JN. Delayed choroidal perfusion in giant cell arteritis. J. Clin. Neuroophthalmol.11(4), 221–227 (1991).
   PubMedGoogle Scholar
• Kaufman D, Dickersin K, Kelman S, Langenberg P, Newman N, Wilson PD. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch. Ophthalmol.118(6), 793–798 (2000).
   PubMedGoogle Scholar
• Newman NJ Scherer R, Langenberg P et al; Ischemic Optic Neuropathy Decompression Trial Research Group. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am. J. Ophthalmol.134(3), 317–328 (2002).
   PubMed Web of Science ®Google Scholar
• Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr. Opin. Neurol.17(1), 27–35 (2004).
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Anterior ischaemic optic neuropathy II. Fundus on ophthalmoscopy and fluorescein angiography. Br. J. Ophthalmol.58, 964–980 (1974).
   PubMed Web of Science ®Google Scholar
• Slavin ML, Barondes MJ. Visual loss caused by choroidal ischemia preceding anterior ischemic optic neuropathy in giant cell arteritis. Am. J. Ophthalmol.117(1), 81–86 (1994).
   PubMed Web of Science ®Google Scholar
• Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog. Retin. Eye Res.24(4), 493–519 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez-Taboada VM, Blanco R, Armona J et al. Giant cell arteritis with an erythrocyte sedimentation rate lower than 50. Clin. Rheumatol.19, 73–75 (2000).
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum.33(8), 1122–1128 (1990).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Balt.)84(5), 277–290 (2005).
   PubMed Web of Science ®Google Scholar
• Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum.45, 140–145 (2001).
   PubMedGoogle Scholar
• Diaz VA, DeBroff BM, Sinard J. Comparison of histopathologic features, clinical symptoms, and erythrocyte sedimentation rates in biopsy-positive temporal arteritis. Ophthalmology112(7), 1293–1298 (2005).
   PubMed Web of Science ®Google Scholar
• Parikh M, Miller NR, Lee AG et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology113, 1842–1845 (2006).
   PubMed Web of Science ®Google Scholar
• Liozon E, Herrmann F, Ly K et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am. J. Med.111(3), 211–217 (2001).
   PubMed Web of Science ®Google Scholar
• Foroozan R, Danesh-Meyer H, Savino PJ. Thrombocytosis in patients with biopsy-proven giant cell arteritis. Ophthalmology109(7), 1267–1271 (2002).
   PubMed Web of Science ®Google Scholar
• Allsop CJ, Gallagher PJ. Temporal artery biopsy in giant-cell arteritis. A reappraisal. Am. J. Surg. Pathol.5(4), 317–323 (1981).
   PubMed Web of Science ®Google Scholar
• Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann. Intern. Med.120, 987–992 (1994).
   PubMed Web of Science ®Google Scholar
• Blumberg S, Giansiracusa DF, Docken WP, Kantrowitz FG. Recurrence of temporal arteritis: clinical recurrence nine years after initial illness. JAMA244, 1713–1714 (1980).
   PubMed Web of Science ®Google Scholar
• Lenton J, Donnelly R, Nash JR. Does temporal artery biopsy influence the management of temporal arteritis? QJM99(1), 33–36 (2006).
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez CMC, Esteban MJ, Cebrian M et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation106(13), 1664–1671 (2002).
   PubMed Web of Science ®Google Scholar
• Chambers WA, Bernardino VB. Specimen length in temporal artery biopsies. J. Clin. Neuroophthalmol.8(2), 121–125 (1988).
   Google Scholar
• Azhar SS, Tang RA, Dorotheo EU. Giant cell arteritis: diagnosing and treating inflammatory disease in older adults. Geriatrics60(8), 26–30 (2005).
   PubMedGoogle Scholar
• Stanson AW. Imaging findings in extracranial (giant cell) temporal arteritis. Clin. Exp. Rheum.18, S43–S48 (2000).
   Google Scholar
• Schmidt WA, Kraft HE, Vorpahl K et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N. Engl. J. Med.6;337(19), 1336–1342 (1997).
   PubMed Web of Science ®Google Scholar
• Schmidt WA. Doppler ultrasonography in the diagnosis of giant cell arteritis. Clin. Exp. Rheumatol.18, S40–S42 (2000).
   PubMed Web of Science ®Google Scholar
• Mitomo T, Funyu T, Takahashi Y et al. Giant cell arteritis and magnetic resonance angiography. Arthritis Rheum.41, 1702 (1998).
   PubMedGoogle Scholar
• Blockmans D, Stroobants S, Maes A et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am. J. Med.15;108, 246–249 (2000).
   Web of Science ®Google Scholar
• De Winter F, Petrovic M, Van de Wiele C et al. Imaging of giant cell arteritis. Evidence of splenic involvement using FDG positron emission tomography. Clin. Nucl. Med.25, 633–634 (2000).
   PubMed Web of Science ®Google Scholar
• Turlakow A, Yeung HWD, Pui J et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch. Intern. Med.161, 1003–1007 (2001).
   PubMedGoogle Scholar
• Frohman LP, Lama P. Annual review of systemic diseases: 1995–1996. Part I. J. Neuroophthalmol.18(1), 67–79 (1998).
   Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology112(6), 1098–103 (2005).
   PubMed Web of Science ®Google Scholar
• Chevalet P, Barrier JH, Pottier P et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol.27(6), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Pipitone N, Boiardi L, Salvarani C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract. Res. Clin. Rheumatol.19(2), 277–292 (2005).
   PubMed Web of Science ®Google Scholar
• Swannell AJ. Polymyalgia rheumatica and temporal arteritis: diagnosis and management. Br. Med. J.314(7090), 1329–32 (1997).
   PubMed Web of Science ®Google Scholar
• Nesher G, Berum Y, Mates M, Nesher R. Rubinow A, Sonnenblick M. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Balt.)83(2), 114–122 (2004).
   PubMed Web of Science ®Google Scholar
• Bergstrom AL, Bengtsson BA, Olsson LB, Malmvall BE, Kutti J. Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. Ann. Rheum. Dis.38(3), 244–247 (1979).
   PubMed Web of Science ®Google Scholar
• Krishna R, Kosmorsky GS. Implications of thrombocytosis in giant cell arteritis. Am. J. Ophthalmol.124(1), 103 (1997).
   PubMed Web of Science ®Google Scholar
• De Keyser J, De Klippel N, Ebinger G. Thrombocytosis and ischaemic complications in giant cell arteritis. Br. Med. J.303(6806), 825 (1991).
   PubMedGoogle Scholar
• Hoffman GS, Cid MC, Hellmann DB et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum.46(5), 1309–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.134(2), 106–114 (2001).
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Di Poi E, Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives. Clin. Exp. Rheumatol.18, S58–S60 (2000).
   Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin. Exp. Rheumatol.19, 495–501 (2001).
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum.44(12), 2933–2935 (2001).
   PubMed Web of Science ®Google Scholar
• Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann. Rheum. Dis.62(4), 373–374 (2003).
   PubMed Web of Science ®Google Scholar
• Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin. Rheumatol.25(1), 109–110 (2006).
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol. Scand.80(4), 355–367 (2002).
   PubMedGoogle Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology110(6), 1204–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Chan CC, Paine M, O’Day J. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis. J. Neuroophthalmol.25(1), 14–17 (2005).
   PubMed Web of Science ®Google Scholar